Articles by Rami Komrokji, MD
Rami Komrokji, MD, describes incorporation of molecular data, tailoring treatment by disease risk, and new therapies in MDS.
The panel mainly focused on how to define and classify MDS and CHIP, as well as how to treat low- and high-risk MDS.
Live in Chicago, this podcast episode features a panel discussion on unanswered questions in AML.
Rami Komrokji, MD, discussed the impact of luspatercept on the genomic landscape in patients with lower-risk MDS.
The crew talk about AML and MDS in this episode of The HemOnc Pulse.
Dr. Komrokji speaks about what might follow the recent FDA approval of luspatercept for certain patients with MDS.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.